{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:07:07Z","timestamp":1792465627170,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T00:00:00Z","timestamp":1710028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.vaccine.2024.03.024","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T22:32:06Z","timestamp":1712356326000},"page":"2966-2974","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021\u201323"],"prefix":"10.1016","volume":"42","author":[{"given":"Pasquale","family":"Stefanizzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Moscara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Venerito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia Annatea","family":"Germinario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Tafuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.03.024_b0005","unstructured":"Gazzetta Ufficiale della Repubblica Italiana Serie Generale n.72 del 24-3-2021 - Allegato. \u201cVaccinazione anti Sars-CoV-2\/COVID-19. Raccomandazioni ad interim sui gruppi target della vaccinazione anti SARS-CoV-2\/COVID-19\u201c 10 marzo 2021. Available online at: https:\/\/www.trovanorme.salute.gov.it\/norme\/renderPdf.spring?seriegu=SG&datagu=24\/03\/2021&redaz=21A01802&artp=1&art=1&subart=1&subart1=10&vers=1&prog=002. Last accessed on October 25, 2023, 2.37 p.m."},{"issue":"4","key":"10.1016\/j.vaccine.2024.03.024_b0010","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.DMIH2-0026-2016","article-title":"Overview of Infections in the Immunocompromised Host","volume":"4","author":"Dropulic","year":"2016","journal-title":"Microbiol Spectr"},{"issue":"3","key":"10.1016\/j.vaccine.2024.03.024_b0015","doi-asserted-by":"crossref","first-page":"2266932","DOI":"10.1080\/21645515.2023.2266932","article-title":"Determinants of compliance to influenza and COVID-19 vaccination in a cohort of solid organ transplant patients in Puglia, Southern Italy (2017\u20132022)","volume":"19","author":"Stefanizzi","year":"2023","journal-title":"Hum Vaccin Immunother"},{"issue":"7","key":"10.1016\/j.vaccine.2024.03.024_b0020","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1093\/cid\/ciz1090","article-title":"Herpes zoster risk in immunocompromised adults in the United States: a systematic review","volume":"71","author":"McKay","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2024.03.024_b0025","doi-asserted-by":"crossref","first-page":"ofw205","DOI":"10.1093\/ofid\/ofw205","article-title":"Risk of herpes zoster in individuals on biologics, disease-modifying antirheumatic drugs, and\/or corticosteroids for autoimmune diseases: a systematic review and meta-analysis","volume":"3","author":"Marra","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"328","key":"10.1016\/j.vaccine.2024.03.024_b0030","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jneuroim.2018.12.009","article-title":"The frequency of varicella-zoster virus infection in patients with multiple sclerosis receiving fingolimod","volume":"15","author":"Aramideh Khouy","year":"2019","journal-title":"J Neuroimmunol"},{"issue":"7","key":"10.1016\/j.vaccine.2024.03.024_b0035","first-page":"1174","article-title":"Safety and immunogenicity of inactivated Varicella-zoster virus vaccine in adults with autoimmune disease: a phase 2, randomized, double-blind","volume":"65","author":"Eberhardson","year":"2017","journal-title":"Placebo-Controlled Clinical Trial Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2024.03.024_b0040","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s15010-011-0162-0","article-title":"Risk of Herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study","volume":"39","author":"Hata","year":"2011","journal-title":"Infection"},{"issue":"3","key":"10.1016\/j.vaccine.2024.03.024_b0045","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1053\/j.ajkd.2011.10.049","article-title":"Risk of herpes zoster in patients treated with long-term hemodialysis: a matched cohort study","volume":"59","author":"Kuo","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.024_b0050","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.ajic.2017.10.004","article-title":"Vaccination coverage in patients affected by chronic diseases: a 2014 cross-sectional study among subjects hospitalized at Bari policlinico general hospital","volume":"46","author":"Gallone","year":"2018","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.vaccine.2024.03.024_b0055","unstructured":"U.S. Food and Drug Administration (FDA). Zostavax. Available online at: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/zostavax. Last accessed on October 25, 2023, 3.48 p.m."},{"key":"10.1016\/j.vaccine.2024.03.024_b0060","unstructured":"European Medicines Agency (EMA). Zostavax, shingles (herpes zoster) vaccine (live). Available online at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zostavax#authorisation-details-section. Last accessed on October 25, 2023, 3.49 p.m."},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2024.03.024_b0065","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1086\/522129","article-title":"Strategies for herpes zoster vaccination of immunocompromised patients","volume":"197","author":"Cohen","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.024_b0070","unstructured":"U.S. Food & Drug administration (FDA). Shingrix. Available online at: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/shingrix. Last accessed on October 25, 2023, 3.57 p.m."},{"key":"10.1016\/j.vaccine.2024.03.024_b0075","unstructured":"European Medicines Agency (EMA). Shingrix, herpes zoster vaccine (recombinant, adjuvanted). Available online at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/shingrix Last accessed on October 25, 2023, 4.09 p.m."},{"key":"10.1016\/j.vaccine.2024.03.024_b0080","unstructured":"European Medicines Agency (EMA). Committee for Medicinal Products for Human Use (CHMP). CHMP extension of indication variation assessment report, dated 23 July 2020 (EMA\/447929\/2020). Available online at: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/shingrix-h-c-4336-ii-0022-epar-assessment-report-variation_en.pdf. Last accessed on October 25, 2023, 4.06 p.m."},{"key":"10.1016\/j.vaccine.2024.03.024_b0085","unstructured":"Gazzetta Ufficiale della Repubblica Italiana - Agenzia Italiana del Farmaco (AIFA). Determina 26 gennaio 2021. Riclassificazione del medicinale per uso umano \u00abShingrix\u00bb, ai sensi dell'articolo 8, comma 10, della legge 24 dicembre 1993, n. 537. (Determina n. DG\/96\/2021). (21A00512) (GU Serie Generale n.31 del 06-02-2021). Available online at: https:\/\/www.gazzettaufficiale.it\/eli\/id\/2021\/02\/06\/21A00512\/sg. Last accessed on October 25, 2023, 4.06 p.m."},{"key":"10.1016\/j.vaccine.2024.03.024_b0090","unstructured":"Regione Puglia \u2013 Dipartimento della salute e del benessere animale. PROT\/12\/10\/2022\/0006807. \u201cDGR 1365\/2022 \u2013 Vaccinazione contro l'Herpes Zoster \u2013 Programma operativo regionale di vaccinazione contro l\u2019Herpes zoster (HZ) \u2013 Documento di indirizzo per l\u2019offerta vaccinale \u2013 Notifica\u201d. Available online at: https:\/\/vaccinarsinpuglia.org\/assets\/uploads\/files\/22\/2022-10-12-direzione-dipartimento-6807-2022-dgr-13-221013-094418.pdf. Last accessed on October 24, 2023, 4.22 p.m."},{"issue":"22","key":"10.1016\/j.vaccine.2024.03.024_b0095","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2024.03.024_b0100","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 Years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2024.03.024_b0105","first-page":"181","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3","volume":"70","author":"Vink","year":"2020","journal-title":"Randomized Clinical Trial Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2024.03.024_b0110","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2024.03.024_b0115","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1080\/21645515.2019.1704124","article-title":"Post-marketing surveillance of adverse events following measles, mumps, rubella and varicella (MMRV) vaccine: retrospecive study in apulia region (ITALY), 2009\u20132017","volume":"16","author":"Stefanizzi","year":"2020","journal-title":"Hum Vaccin Immunother"},{"issue":"33","key":"10.1016\/j.vaccine.2024.03.024_b0120","first-page":"154","article-title":"Systematic use of causality assessment in AEFI surveillance: a 2013\u20132016 pilot study in Puglia","volume":"12","author":"Stefanizzi","year":"2017","journal-title":"Euromediter Biomed J"},{"issue":"13","key":"10.1016\/j.vaccine.2024.03.024_b0125","article-title":"Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: a systematic review and network meta-analysis","volume":"30","author":"Xia","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2024.03.024_b0130","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1097\/RHU.0000000000001790","article-title":"A medical records review study assessing safety of zoster vaccine recombinant, adjuvanted in patients with rheumatic disease","volume":"28","author":"Gupta","year":"2022","journal-title":"J Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.vaccine.2024.03.024_b0135","doi-asserted-by":"crossref","first-page":"6967","DOI":"10.3390\/ijms24086967","article-title":"Immunogenicity and safety of adjuvanted recombinant zoster vaccine in rheumatoid arthritis patients on anti-cellular biologic agents or JAK inhibitors: a prospective observational study","volume":"24","author":"Venerito","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.vaccine.2024.03.024_b0140","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/art.42261","article-title":"Recombinant zoster vaccine uptake and risk of Flares among older adults with immune-mediated inflammatory diseases in the US","volume":"74","author":"Leung","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.vaccine.2024.03.024_b0145","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/ecco-jcc\/jjac040","article-title":"Safety of recombinant zoster vaccine in patients with inflammatory bowel disease","volume":"16","author":"Khan","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.vaccine.2024.03.024_b0150","unstructured":"Gazzetta Ufficiale della Repubblica Italiana \u2013 Ministero della Salute. Decreto 30 Aprile 2015. \u201cProcedure operative e soluzioni tecniche per un'efficace azione di farmacovigilanza adottate ai sensi del comma 344 dell'articolo 1 della legge 24 dicembre 2012, n. 228 (Legge di stabilita' 2013). (15A04666) (GU Serie Generale n.143 del 23-06-2015)\u201d. Available online at: https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2015-06-23&atto.codiceRedazionale=15A04666 . Last accessed on October 25, 2023, 7.04 p.m."},{"issue":"14","key":"10.1016\/j.vaccine.2024.03.024_b0155","doi-asserted-by":"crossref","first-page":"1074246","DOI":"10.3389\/fimmu.2023.1074246","article-title":"Allergic adverse events following immunization: data from post-marketing surveillance in Apulia region (South of Italy)","volume":"27","author":"Stefanizzi","year":"2023","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2024.03.024_b0160","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.vaccine.2018.01.018","article-title":"Systematic causality assessment of adverse events following HPV vaccines: analysis of current data from Apulia region (Italy)","volume":"36","author":"Tafuri","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.024_b0165","unstructured":"European Medicines Agency (EMA). Shingrix, INN-Herpes zoster vaccine (recombinant, adjuvanted). Annex I, summary of product characteristics. Available online at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/shingrix-epar-product-information_en.pdf. Last accessed on October 25, 2023, 7.16 p.m."},{"issue":"12","key":"10.1016\/j.vaccine.2024.03.024_b0170","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3390\/jpm11121283","article-title":"COVID-19 vaccine does not increase the risk of disease Flare-ups among patients with autoimmune and immune-mediated diseases","volume":"11","author":"Pinte","year":"2021","journal-title":"J Pers Med"},{"issue":"5","key":"10.1016\/j.vaccine.2024.03.024_b0175","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/0961203310388445","article-title":"International consensus for a definition of disease flare in lupus","volume":"20","author":"Ruperto","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.vaccine.2024.03.024_b0180","doi-asserted-by":"crossref","first-page":"102947","DOI":"10.1016\/j.msard.2021.102947","article-title":"Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? a retrospective study","volume":"52","author":"Barzegar","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"11","key":"10.1016\/j.vaccine.2024.03.024_b0185","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.3324\/haematol.2022.280702","article-title":"Relapse of immune-mediated thrombotic thrombocytopenic purpura following mRNA COVID-19 vaccination: a prospective cohort study","volume":"107","author":"Giuffrida","year":"2022","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.vaccine.2024.03.024_b0190","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/ibd\/izab302","article-title":"Impact of SARS-CoV-2 vaccination on inflammatory bowel disease activity and development of vaccine-related adverse events: results from PREVENT-COVID","volume":"28","author":"Weaver","year":"2022","journal-title":"Inflamm Bowel Dis"},{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2024.03.024_b0195","article-title":"Clinical evaluation of immunological and clinical recurrence of immune-mediated nephropathies after SARS-COV-2 vaccine","volume":"37","author":"Musetti","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1016\/j.vaccine.2024.03.024_b0200","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/jiu606","article-title":"Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1\/2a randomized, placebo-controlled study","volume":"211","author":"Berkowitz","year":"2015","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2024.03.024_b0205","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1093\/rheumatology\/keab139","article-title":"Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients","volume":"60","author":"Lenfant","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.vaccine.2024.03.024_b0210","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3390\/vaccines9050456","article-title":"Post-Marketing active surveillance of adverse reactions following influenza cell-based quadrivalent vaccine: an italian prospective observational study","volume":"9","author":"Stefanizzi","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"4","key":"10.1016\/j.vaccine.2024.03.024_b0215","doi-asserted-by":"crossref","first-page":"91","DOI":"10.15585\/mmwr.mm6804a4","article-title":"Postlicensure safety surveillance of recombinant zoster vaccine (shingrix) - United States, october 2017-june 2018","volume":"68","author":"Hesse","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"10.1016\/j.vaccine.2024.03.024_b0220","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/acr2.11150","article-title":"Safety of the zoster vaccine recombinant adjuvanted in rheumatoid arthritis and other systemic rheumatic disease patients: a single center's experience with 400 patients","volume":"2","author":"Stevens","year":"2020","journal-title":"ACR Open Rheumatol"},{"issue":"5","key":"10.1016\/j.vaccine.2024.03.024_b0225","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/aje\/kwac030","article-title":"A broad safety assessment of the recombinant herpes zoster vaccine","volume":"191","author":"Yih","year":"2022","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.024_b0230","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/vaccines11010151","article-title":"Current evidence on vaccinations in pediatric and adult patients with systemic autoinflammatory diseases","volume":"11","author":"Massaro","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"14","key":"10.1016\/j.vaccine.2024.03.024_b0235","doi-asserted-by":"crossref","first-page":"1078736","DOI":"10.3389\/fimmu.2023.1078736","article-title":"Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: a dutch cohort study and review of the literature","volume":"30","author":"Duijster","year":"2023","journal-title":"Front Immunol"},{"issue":"363","key":"10.1016\/j.vaccine.2024.03.024_b0240","doi-asserted-by":"crossref","first-page":"k4029","DOI":"10.1136\/bmj.k4029","article-title":"Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis","volume":"25","author":"Tricco","year":"2018","journal-title":"BMJ"},{"issue":"48","key":"10.1016\/j.vaccine.2024.03.024_b0245","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1016\/j.vaccine.2023.09.061","article-title":"Adverse events following immunization (AEFIs) with anti-meningococcus type B vaccine (4CMenB): data of post-marketing active surveillance program. Apulia Region (Italy), 2019-2023","volume":"41","author":"Stefanizzi","year":"2023","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2024.03.024_b0250","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1080\/21645515.2019.1627818","article-title":"Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials","volume":"15","author":"Oostvogels","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.vaccine.2024.03.024_b0255","first-page":"e36005","article-title":"Side effects of COVID-19 vaccines among diabetic subjects and healthy individuals","volume":"15","author":"Khan","year":"2023","journal-title":"Cureus"},{"issue":"13","key":"10.1016\/j.vaccine.2024.03.024_b0260","doi-asserted-by":"crossref","first-page":"919979","DOI":"10.3389\/fimmu.2022.919979","article-title":"The Flare of rheumatic disease after SARS-CoV-2 vaccination: a review","volume":"4","author":"Xie","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2024.03.024_b0265","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jocn.2022.08.012","article-title":"Multiple sclerosis relapse after COVID-19 vaccination: a case report-based systematic review","volume":"104","author":"Nabizadeh","year":"2022","journal-title":"J Clin Neurosci."},{"issue":"SI2","key":"10.1016\/j.vaccine.2024.03.024_b0270","doi-asserted-by":"crossref","first-page":"SI143","DOI":"10.1093\/rheumatology\/keac249","volume":"61","author":"Rider","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.vaccine.2024.03.024_b0275","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1080\/21645515.2021.1953346","article-title":"Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice","volume":"17","author":"Stadtmauer","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"2019","key":"10.1016\/j.vaccine.2024.03.024_b0280","first-page":"6764154","article-title":"Immunization campaigns and strategies against human papillomavirus in Italy: the results of a survey to regional and local health units representatives","volume":"4","author":"Trucchi","year":"2019","journal-title":"Biomed Res Int"},{"issue":"3","key":"10.1016\/j.vaccine.2024.03.024_b0285","doi-asserted-by":"crossref","first-page":"100860","DOI":"10.1016\/j.accpm.2021.100860","article-title":"Willingness to get a COVID-19 vaccine among critical care non-medical healthcare workers and impact of a vaccine information session","volume":"40","author":"Gakuba","year":"2021","journal-title":"Anaesth Crit Care Pain Med"},{"issue":"9","key":"10.1016\/j.vaccine.2024.03.024_b0290","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1111\/jan.15222","article-title":"A large cross-sectional survey of COVID-19 vaccination willingness amongst healthcare students and professionals: reveals generational patterns","volume":"78","author":"Tomietto","year":"2022","journal-title":"J Adv Nurs"},{"issue":"3","key":"10.1016\/j.vaccine.2024.03.024_b0295","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3390\/vaccines8030358","article-title":"Strategies to improve vaccination among at-risk adults and the elderly in Italy","volume":"8","author":"Calabr\u00f2","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"10.1016\/j.vaccine.2024.03.024_b0300","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/pathophysiology30020014","article-title":"Challenges in the vaccination of the elderly and strategies for improvement","volume":"30","author":"Soegiarto","year":"2023","journal-title":"Pathophysiology"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.024_b0305","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/vaccines8010034","article-title":"Vaccination programs for adults in Europe, 2019","volume":"8","author":"Cassimos","year":"2020","journal-title":"Vaccines (Basel)"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24003116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24003116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T05:54:29Z","timestamp":1725688469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24003116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":61,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0264410X24003116"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.024","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021\u201323","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}